Eloxx CEO granted 328,833 stock options

Eloxx Pharmaceuticals, Inc. reported that President and CEO Sumit Aggarwal received a grant of stock options covering 328,833 shares of common stock.

Rhea-AI Filing Summary

Eloxx Pharmaceuticals, Inc. reported that President and CEO Sumit Aggarwal received a grant of stock options covering 328,833 shares of common stock. These options have an exercise price of $1.65 per share and expire on September 19, 2035.

The options were originally granted on September 19, 2025 and were subject to a performance-based vesting condition that was satisfied on June 10, 2026. Vesting will occur as to 1/36 of the options on July 31, 2026, with the remaining options vesting in equal monthly installments over the following 35 months, contingent on Aggarwal’s continued service.

Insider Trade Summary

Grant/Award: 328,833 shares

Grant/Award 1 txn

Insider Aggarwal Sumit

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	328,833	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 328,833 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on September 19, 2025 and was subject to a performance-based vesting condition that was satisfied on June 10, 2026. The option will vest as to 1/36 on July 31, 2026, with the remaining options vesting in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuing service on each such vesting date.

Key Figures

Options granted: 328,833 options Exercise price: $1.65 per share Expiration date: September 19, 2035 +3 more

6 metrics

Options granted 328,833 options Stock Option (Right to Buy) grant to CEO

Exercise price $1.65 per share Option conversion or exercise price

Expiration date September 19, 2035 Option expiration

Initial vesting date July 31, 2026 1/36 of options vest

Remaining vesting period 35 months Equal monthly vesting after initial tranche

Shares underlying options 328,833 shares Common stock underlying this option award

Key Terms

Stock Option (Right to Buy), performance-based vesting condition, vesting date, exercise price, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

performance-based vesting condition financial

"was subject to a performance-based vesting condition that was satisfied"

vesting date financial

"subject to the Reporting Person's continuing service on each such vesting date"

exercise price financial

"conversion_or_exercise_price: 1.6500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ELOX CEO Sumit Aggarwal report in this Form 4?

Sumit Aggarwal reported a grant of stock options for 328,833 shares of Eloxx Pharmaceuticals common stock. The filing shows this as a compensation-related award, not an open-market purchase or sale.

What is the exercise price of the new ELOX stock options?

The stock options granted to Sumit Aggarwal carry an exercise price of $1.65 per share. This is the price he must pay per share to convert the options into Eloxx common stock in the future.

How do the ELOX CEO’s options vest over time?

The options begin vesting 1/36 on July 31, 2026, with the remaining portions vesting in equal monthly installments over the next 35 months. Vesting continues only while Sumit Aggarwal remains in service with Eloxx Pharmaceuticals.

What performance condition affected the ELOX option grant?

The option grant was subject to a performance-based vesting condition that was satisfied on June 10, 2026. Only after this condition was met does the time-based monthly vesting schedule start for the CEO’s stock options.

When do the ELOX CEO’s stock options expire?

The stock options granted to Sumit Aggarwal expire on September 19, 2035. After that expiration date, any unexercised options will lapse and can no longer be used to purchase Eloxx common stock.

How many ELOX options does the CEO hold after this transaction?

Following this grant, Sumit Aggarwal is shown holding 328,833 stock options. Each option is a right to buy one share of Eloxx Pharmaceuticals common stock at the fixed exercise price of $1.65 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 08:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aggarwal Sumit

(Last) (First) (Middle)

C/O ELOXX PHARMACEUTICALS, INC.

P.O. BOX 274

(Street)

ARLINGTON MASSACHUSETTS 02476

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc. [ ELOX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.65	06/10/2026		A		328,833		(1)	09/19/2035	Common Stock	328,833	$0	328,833	D

Explanation of Responses:

1. The option was granted on September 19, 2025 and was subject to a performance-based vesting condition that was satisfied on June 10, 2026. The option will vest as to 1/36 on July 31, 2026, with the remaining options vesting in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuing service on each such vesting date.

	/s/ Sumit Aggarwal	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)